<DOC>
	<DOC>NCT02234089</DOC>
	<brief_summary>The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen deprivation therapy (Degarelix or LHRH agonists).</brief_summary>
	<brief_title>Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormon-Releasing-Hormon (LHRH) Agonists.</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Diagnosed with Prostate Cancer and indicated for ADT according to Summary of Product Characteristics (SmPC) Decision made to prescribe ADT (Degarelix or LHRH agonist) prior to enrolment Patient had previous or is currently under hormonal management of Prostate Cancer, except for a curative intention, where the duration of the neoadjuvant/adjuvant therapy did not exceed 6 months and treatment should have been terminated at least 6 months prior to baseline. Participation in a clinical trial at baseline and during the followup period</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>